---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-066364"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2026-06-08T21:15:17+00:00"
generated_at: "2026-06-08T21:16:37.585199+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics closes $8.5M private placement with warrants for up to $23.7M total

## Summary
- Closed private placement of 3,655,917 common shares (or pre-funded warrants) plus Series G and H warrants at $2.325/unit, raising $8.5M gross.
- Net proceeds of ~$7.7M after placement agent fees; cash runway extended into Q1 2027, beyond expected FDA submission.
- If all warrants exercised for cash, additional $15.2M proceeds would extend cash runway well beyond FDA approval and first year of commercialization.
- Company must file resale registration statement by June 17, 2026 for underlying shares; warrants have exercise price $2.075.

## SEC filing metadata
- accession: 0001213900-26-066364
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2026-06-08T21:15:17+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390026066364/0001213900-26-066364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390026066364/ea0293390-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-066364
- JSON: https://secwatch.observer/filing/0001213900-26-066364.json
- Plain text: https://secwatch.observer/filing/0001213900-26-066364.txt

## Key facts
- Equity Issuances
  Bluejay Diagnostics, Inc. issued pre-funded warrants to purchase up to 3,655,917 shares; Series G warrants to purchase up to 3,655,917 shares; Series H warrants to purchase up to 3,655,917 shar of warrant to institutional accredited investors for $2.324 per Pre-Funded Warrant and accompanying Series G Warrant and Series H Warrant.
  - Security: warrant
  - Shares: pre-funded warrants to purchase up to 3,655,917 shares; Series G warrants to purchase up to 3,655,917 shares; Series H warrants to purchase up to 3,655,917 shar
  - Purchaser: institutional accredited investors
  - Consideration: $2.324 per Pre-Funded Warrant and accompanying Series G Warrant and Series H Warrant
  source text: and (iii) Series H warrants (the “Series H Warrants”) to purchase up to 3,655,917 shares of common stock. The combined price of securities sold in the private placement was $2.324 per Pre-Funded Warrant and accompanying Series G Warrant and Series H Warrant. The Pre-Funded Warrants are immediately exercisable for shares of common stock at an exercise price
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390026066364/0001213900-26-066364-index.htm
- Equity Issuances
  Bluejay Diagnostics, Inc. issued Placement Agent Warrants to purchase up to an aggregate of 255,915 shares of common stock of warrant to H.C. Wainwright & Co. for services as placement agent.
  - Security: warrant
  - Shares: Placement Agent Warrants to purchase up to an aggregate of 255,915 shares of common stock
  - Purchaser: H.C. Wainwright & Co.
  - Consideration: services as placement agent
  source text: the Company issued to the placement agent (or its designees) warrants ("Placement Agent Warrants"
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390026066364/0001213900-26-066364-index.htm
- Material Agreements
  Bluejay Diagnostics, Inc. entered into registration rights agreement with certain institutional, accredited investors (effective 2026-06-02).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional, accredited investors
  - Effective: 2026-06-02
  source text: On June 2, 2026, Bluejay Diagnostics, Inc. (the “Company”), in connection with a private placement of the Company’s securities, entered into with certain institutional, accredited investors (i) a securities purchase agreement, and (ii) a registration rights agreement (the “private placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390026066364/0001213900-26-066364-index.htm
- Material Agreements
  Bluejay Diagnostics, Inc. entered into securities purchase agreement with certain institutional, accredited investors valued at approximately $7.7 million (effective 2026-06-02).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional, accredited investors
  - Value: approximately $7.7 million
  - Effective: 2026-06-02
  source text: On June 2, 2026, Bluejay Diagnostics, Inc. (the “Company”), in connection with a private placement of the Company’s securities, entered into with certain institutional, accredited investors (i) a securities purchase agreement, and (ii) a registration rights agreement (the “private placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390026066364/0001213900-26-066364-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.